Navigation Links
Targeting the Adrenal Gland Could Be Key Against Heart Failure

pled receptor kinase 2, essentially turning them off. Using gene therapy to block adrenal gland GRK2 in animals in heart failure, the scientists were able to get the alpha 2 receptors working again and also found that the beta adrenergic receptors on the heart worked better as well.

“We’ve shown that in the adrenal gland, resetting the alpha adrenergic receptors by inhibiting GRK2 causes more normal regulation and the proper feedback control, and catecholamines are lowered,” explains Dr. Koch, who also heads the George Zallie and Family Laboratory of Cardiovascular Gene Therapy in the Department of Medicine. “If less catecholamine is presented to the heart, then the beta receptors restabilize and that improves heart function. The heart is allowed to relax and get better.”

“This is the first time anyone has identified a molecular mechanism involved in such sympathetic overdrive in heart failure,” adds study first author Anastasios Lymperopoulos, Ph.D., a postdoctoral fellow in the Center for Translational Medicine, and means that adrenal gland GRK2 becomes a new target for heart failure medications.

“GRK2 inhibitors would be a totally new class of drugs if they come on the market,” Dr. Koch says, adding that eventually, human gene therapy for heart failure could be feasible.
Source-Newswise
SRM
'"/>




Page: 1 2

Related medicine news :

1. Novel Technique For Targeting Small-Cell Lung Cancer
2. Targeting PARP1 Is Effective In Protecting HD Cells from Damage
3. Ad Campaign Targeting Republicans On Medicare Prescription Drug Program
4. By Targeting Specific Germs, Hospital Hopes to Improve Pneumonia Treatment
5. Highly Potent TB Strain Plays Favorites Targeting Specific Ethnic Groups
6. New Asthma Medicine Targeting Vulnerable Inner-City Children Tested
7. Targeting a Single Gene Could Inhibit Bone Decay and Stimulate Bone Growth
8. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
9. Targeting SOCS-3 can Control Obesity
10. Sex Abstinence Programs Targeting School-goers may Not Produce Desired Effect , Study
11. Adrenal Suppression not predicted by inhaled corticosteroids
Post Your Comments:
(Date:12/1/2008)...c. 1 Accuray Incorporate... of radiosurgery, announced today,that Fox Chase ...rKnife(R),Robotic Radiosurgery System. The CyberK...installed in Pennsylvania, and will be housed in a...ion in Buckingham, Pa. , Established in 190...
(Date:12/1/2008)...swire-FirstCall/ -- Affiliated Computer Services,...market with innovative solutions,designed to help... service.,With the expiration of an agreement tha... ACS can now offer its proven business process and...As the U.S. faces economic uncertainty, ACS will b...
(Date:12/1/2008)...ec. 1 Question. What would happen ...cle-building exercise? The,fitness world would ce...,membership fees would have to close. 2. Phony ex...existent. 3. We would never have to spend another ...ndustry,s take-home pay is now estimated at 35 bil...
(Date:12/1/2008)... Dr. Brian Snyder, a neurosurgeon at Neurologi...tate-of-the-art treatments in which he is speciall...used by neurological diseases. Neurological Surger... highly trained doctors in the New York area. Asid...tice also offers MRI testing, pain management, neu...
Breaking Medicine News(10 mins):Health News:Fox Chase Cancer Center Purchases CyberKnife System 2Health News:Fox Chase Cancer Center Purchases CyberKnife System 3Health News:Fox Chase Cancer Center Purchases CyberKnife System 4Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 2Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor 2Health News:Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor 3
...distiller's grains can be fed in a steam-flaked co... researchers//. The two four-month cattle finish...ed by Dr. Mike Brown, a Texas Agricultural Experim...st Texas A&M University associate professor, and D...
...ove an abbreviated new drug application (ANDA) for...ons of safety or efficacy// , the agency had to de...oving any generic version. The investigation fou...ues, and the FDA has announced that it can approve...
...n Wednesday rejected to consider Delhi government'...sions from three years to three-and-a-half years//...and Justice Sanjeev Khanna referred the matter to ...en set up to look into the aspect of admission pro...
...onal autism study has grim facts to state. The stu...between 6 and 12 have autism// and that it also ta...velopmental disorder. In addition, around 125,000...tism indicted by impaired communication problems, ...
Other Medicine News:Health News:Wet Distiller's Grains Could Play a Role in Cattle Diets 2Health News:Wet Distiller's Grains Could Play a Role in Cattle Diets 3
(Date:11/25/2008)... Nov. 25 Poniard,Pharma...ical company focused on,innovative oncology thera...trategic alternatives for its preclinical research...its resources on the clinical development of picop... the initial commercialization of,picoplatin in t...
(Date:11/25/2008)...nical Trial to Assess Survival of Patients Receivi...sectable Hepatocellular Carcinoma , , BELLE... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
(Date:11/24/2008)...Japan, Nov. 24 Takeda Pharmaceutic..., Takeda Global Research & Development Center,...visory Committee of the U.S. Food and Drug Adminis...uxostat for the treatment of hyperuricemia in pat...of approval, with one panel member abstaining. The...
(Date:11/24/2008)...RNewswire-FirstCall/ -- Leaders of Schering-Plough...te for investors on the company,s research pipelin...at includes 46 new entities in clinical trials or ...ies. , , "Research and development is addin...ntinue our transformation," said Fred Hassan, chai...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Dr Gail Golab Head of AVMA Animal Welfare Division Becomes First U S Veterinarian Credentialed in Animal Welfare 26944 1Dr Gail Golab Head of AVMA Animal Welfare Division Becomes First U S Veterinarian Credentialed in Animal Welfare 26944 2SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 26942 1SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 26942 2Tennessee Introduces Long Term Care Partnership Insurance Policies and Producer Training Requirement 26940 1Tennessee Introduces Long Term Care Partnership Insurance Policies and Producer Training Requirement 26940 2Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 1Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 2Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 3
...lammation After,Menopause; Weight-Loss Surgery Imp...ce, ALEXANDRIA, Va., March 28, 2007 /PRNewswire/ -...to develop Parkinson,s disease as,they age, though...ink between the two diseases, according to a new s...s Care. , The study, by researchers in Finland, is...
...ges of nifedipine,GITS therapy , , ,LEVERKUSEN, ...shed articles in the Journal of Clinical Epidemiol...ong-acting calcium channel,blocker (CCB) nifedipin...nd its blood pressure lowing effect. A first,publi...demiology,2007; first published online) demonstrat...
Other Medicine Technology:Diabetes Linked to Higher Parkinson's Risk 2Diabetes Linked to Higher Parkinson's Risk 3Diabetes Linked to Higher Parkinson's Risk 4Calcium Channel Blocker Adalat GITS Offer Additional Benefits 2Calcium Channel Blocker Adalat GITS Offer Additional Benefits 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: